3 views left Get unlimited views with a free account

Subscribe to GlobalData Explorer

Explore the latest trends and actionable insights on the Neuroblastoma Clinical Trials to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Neuroblastoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 177 ongoing clinical trials involving Neuroblastoma
Of the 177 trials,72 trials are in Phase II
Furthermore, 48 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Neuroblastoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Neuroblastoma, an Oncology condition. The largest number of ongoing clinical trials for Neuroblastoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Neuroblastoma-related drug trials.

National Cancer Institute US: The leading ongoing Neuroblastoma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Neuroblastoma-related ongoing clinical trials.

Children's Oncology Group, Memorial Sloan Kettering Cancer Center, Atrium Health and Y-mAbs Therapeutics Inc are among other notable clinical trial sponsors involved in Neuroblastoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Neuroblastoma

Dinutuximab (Unituxin), Pegylated liposomal doxorubicin (Doxil, Caelyx) and Melphalan (Alkeran, Melphalan Hydrochloride) are among the key marketed drugs involving Neuroblastoma.

Dinutuximab (Unituxin) is a chimeric monoclonal antibody, composed of a combination of mouse and human DNA acts as an anti-neoplastic agent. It functions via Cytotoxic to Cells Expressing Ganglioside GD2 mechanism of action. Dinutuximab is formulated as solution, concentrate solution for intravenous or Intravenous drip route of administration. Dinutuximab was first approved in 2015 and is marketed globally in the US, Canada, Germany, and Japan by United Therapeutics Corp.

Pegylated liposomal doxorubicin (Doxil, Caelyx) is an anthracycline topoisomerase inhibitor isolated from Streptomyces peucetius var. caesius. It functions via DNA Synthesis Inhibitor; DNA Topoisomerase II (EC 5.99.1.3) Inhibitor mechanism of action. Pegylated liposomal doxorubicin is formulated as concentrate suspension pegylated liposomal injection for intravenous infusion administration. Pegylated liposomal doxorubicin was first approved in 1995 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Baxter International Inc.

Explore the latest trends and actionable insights on the Neuroblastoma Clinical Trials to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Neuroblastoma Clinical Trials to inform business strategy and pinpoint opportunities and risks. Visit Report Store